Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

perating expenses and its R & D programs with the objective of rapidly aligning its cost structure to its revenue projections and R & D opportunities. When the Board has approved a revised operating plan, the Company will update its guidance for revenues and expenses. Other key Company priorities include non-dilutive finance options which include product out-license transactions and the monetization of its SANCTURA(R) and SANCTURA XR royalty streams and the retirement or restructuring of the Company's convertible debt which matures in July 2009.

As part of the realignment, the Company is also announcing that Thomas F. Farb, its president and chief operating officer and Kurt Lewis, its senior vice president, sales and marketing are leaving the Company to pursue other opportunities. Mr. Lewis' position has been filled by Nancy Bryan, vice president, global marketing, who becomes senior vice president, sales and marketing. Before joining Indevus, Ms. Bryan was senior vice president, head of commercial at Elan for the autoimmune franchise, vice president of marketing for men's health at Bayer Pharmaceuticals and held various positions at Merck and Glaxo Wellcome.

Dr. Cooper added, "I would like to thank Tom Farb and Kurt Lewis for their service to the Company. Tom was instrumental in our acquisition of Valera Pharmaceuticals and has provided excellent leadership as president. He played a key role in preparing the Company for the launch of NEBIDO which is now delayed and will assist us with the development of a revised operating plan during the next month. Kurt has led the successful launch of SUPPRELIN LA, increased market share for VANTAS, and has been instrumental in the pre-launch planning for VALSTAR and NEBIDO. We wish Tom and Kurt all the best in their new endeavors."

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat condit
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces ... comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact ... chemically resistant and maintenance-free solution for a broad range of vacuum filtration applications. ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... ... 31, 2015 , ... Global Resorcinol Market 2015-2019 is a ... the global resorcinol industry. The report highlights the various growth prospects and the ... analysis of primary and secondary inputs from the existing players of the resorcinol ...
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Research conducted at The,Walter and Eliza Hall ... licensing agreement signed between Australian biotechnology company,Bionomics, ... Under the Development and Licensing Agreement, Merck ... multiple sclerosis (MS) and other autoimmune,conditions. These ...
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today announced ... Vice President,of Human Resources., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Mr. Zhu worked as Head of Asia Human,Resources ...
... Antonio (June 30, 2008) Researchers at The University of ... Infectious Diseases and The University of Texas Health Science Center ... to play a role in controlling the early infectious process ... agent that is the cause of tularemia. The findings will ...
Cached Biology Technology:MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR 2UTSA/UTHSCSA publish results on bio-threat agent 2
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... poisonous frog was recently discovered in a remote mountainous ... supported by the Conservation Leadership Programme (CLP). The new ... given the name the ?golden frog of Supat. ... to several other common species in the area. However, ...
... of highly organized epithelial cells line all the cavities ... the movement of liquids,and cells in the body organs. ... serve as a barrier against cancer, according to a,study ... week in,the online edition of the Proceedings of the ...
... today by the Health Department shed new light on the ... who responded to the World Trade Center disaster on September ... Health Registry, show that 3.6% of the 25,000 rescue and ... working at the site. That rate is 12 times what ...
Cached Biology News:Cells united against cancer 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 3